Welcome to our dedicated page for Oxbridge Re Hldg SEC filings (Ticker: OXBRW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oxbridge Re Holdings Limited Warrant expiring 3/26/2029 (NASDAQ: OXBRW) is linked to Oxbridge Re Holdings Limited, a Cayman Islands–incorporated company whose ordinary shares trade under the symbol OXBR. On Stock Titan’s SEC filings page for OXBRW, you can review regulatory documents filed by Oxbridge Re that relate to both its equity and its listed warrants, including OXBRW.
Oxbridge Re’s SEC filings provide detail on its activities as a property and casualty reinsurer and as a participant in tokenized Real-World Assets (RWAs). In Forms 8-K, the company has disclosed items such as an Equity Distribution Agreement for at-the-market offerings of ordinary shares, the adoption of the Oxbridge Re Holdings Limited 2025 Omnibus Incentive Plan, and amendments to its memorandum and articles of association to increase authorized share capital. These filings also describe executive employment agreements and corporate action, change of control, and performance agreements that grant restricted share units upon certain triggering events.
Through its Definitive Proxy Statement (DEF 14A), Oxbridge Re outlines proposals presented to shareholders, including increases in authorized share capital and approval of the 2025 Omnibus Incentive Plan. Together, these documents help investors understand the company’s capital structure, governance framework, and potential sources of dilution, all of which are relevant when evaluating the underlying ordinary shares and derivative securities such as OXBRW.
On Stock Titan, SEC filings for Oxbridge Re are supplemented with AI-powered summaries that explain key points in accessible language. Investors can quickly see the main terms of material agreements, equity plans, and capital-raising programs without reading every page of the original documents. The filings page updates as new reports are posted to EDGAR, giving users a current view of Oxbridge Re’s regulatory disclosures, including 8-Ks, proxy statements, and other filings that may affect the value and risk profile of the OXBRW warrant and the underlying OXBR shares.
Oxbridge Re Holdings Limited (Nasdaq: OXBR) filed an 8-K on 9 July 2025 announcing it has entered into a new $5 million at-the-market Equity Distribution Agreement with Maxim Group LLC. The agreement authorises the agent to sell ordinary shares from time to time on the Nasdaq Capital Market or other trading venues at prevailing prices. Either party may terminate the arrangement with 30 days’ notice or once the full $5 million capacity is reached. Oxbridge will pay a 3.0 % sales commission on gross proceeds.
The facility replaces the September 30 2022 ATM agreement under which the company raised $4.6 million. The company is under no obligation to issue shares and may instruct the Sales Agent on price, time and amount parameters. Net proceeds are earmarked for general corporate purposes, including funding of the company’s reinsurance operations; pending deployment, proceeds will be invested in cash or short-term investment-grade instruments.
Shares offered under the ATM are being drawn from the company’s existing shelf registration statement (Form S-3, File No. 333-287186). In line with General Instruction I.B.6, up to $517,745 of ordinary shares are currently registered, with additional prospectus supplements required for further capacity. Supporting documents include the Equity Distribution Agreement (Exhibit 1.1) and Cayman legal opinion (Exhibit 5.1).
Oxbridge Re Holdings Ltd. (Ticker: OXBRW) – Schedule 13D/A (Amendment No. 2)
The filing updates the beneficial ownership of a coordinated reporting group led by Allan S. Martin and related entities. The group now controls a combined 964,422 ordinary shares (12.07% of outstanding) through direct holdings and warrant-exercisable shares. Key ownership breakdown:
- Allan S. Martin: 964,422 shares (incl. 547,298 warrant-exercisable), sole voting/dispositive power 0; shared 964,422.
- Marie B. Martin: 424,697 shares (5.53%), sole voting/dispositive 34,664; shared 390,033.
- Fleur de Lis Partners, LLLP: 317,770 shares (4.13%), all shared voting/dispositive.
- Allan S Martin Children’s IRRV Trust: 34,664 shares (≈1%).
- Martin Family Foundation, Inc.: 146,723 shares (≈1%).
The securities were acquired with personal funds “for investment purposes.” No plans for corporate actions are disclosed.
Recent transactions (Schedule A, past 60 days):
- Open-market sales: four blocks of 1,000 shares each on 3 Jul 2025 at weighted prices between $2.0312–$2.1350.
- Inter-family transfer: 25,000-share gift on 7 Jul 2025 from Allan & Marie Martin to the Martin Family Foundation; reciprocal transfer recorded for reporting purposes.
Following these trades, Mr. Martin remains the largest outside shareholder, exceeding the 5% threshold that triggers 13D reporting. The filing contains no new financing arrangements, litigation, or proposals affecting control. All signatories certified the accuracy of the statement on 7 Jul 2025.